These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 2464932

  • 21. Maternal serum alphafetoprotein screening. University Medical Center.
    Morris N, Riconda D, Marfatia L, Ostrer H.
    J Fla Med Assoc; 1991 Jun; 78(6):365-8. PubMed ID: 1714937
    [Abstract] [Full Text] [Related]

  • 22. Impact of folic acid fortification in the United States: markedly diminished high maternal serum alpha-fetoprotein values.
    Evans MI, Llurba E, Landsberger EJ, O'Brien JE, Harrison HH.
    Obstet Gynecol; 2004 Mar; 103(3):474-9. PubMed ID: 14990409
    [Abstract] [Full Text] [Related]

  • 23. Routine assessment of amniotic fluid alpha-Fetoprotein in early second-trimester amniocentesis is no longer justified.
    Widlund KF, Gottvall T.
    Acta Obstet Gynecol Scand; 2007 Mar; 86(2):167-71. PubMed ID: 17364279
    [Abstract] [Full Text] [Related]

  • 24. Free beta hCG screening of hydropic and non-hydropic Turner syndrome pregnancies.
    Laundon CH, Spencer K, Macri JN, Anderson RW, Buchanan PD.
    Prenat Diagn; 1996 Sep; 16(9):853-6. PubMed ID: 8905900
    [Abstract] [Full Text] [Related]

  • 25. Periodic health examination, 1994 update: 3. Primary and secondary prevention of neural tube defects. Canadian Task Force on the Periodic Health Examination.
    CMAJ; 1994 Jul 15; 151(2):159-66. PubMed ID: 7518734
    [Abstract] [Full Text] [Related]

  • 26. [Maternal serum screening for congenital abnormalities and Down syndrome in Sønderjylland County. Eight years of experience].
    Christiansen M, Petersen PL, Permin M, Larsen LA, Nørgaard-Pedersen B.
    Ugeskr Laeger; 1999 Dec 13; 161(50):6928-34. PubMed ID: 10643380
    [Abstract] [Full Text] [Related]

  • 27. Triploid partial molar pregnancy detected through maternal serum alpha-fetoprotein and HCG screening.
    Harper MA, Ruiz C, Pettenati MJ, Rao PN.
    Obstet Gynecol; 1994 May 13; 83(5 Pt 2):844-6. PubMed ID: 7512706
    [Abstract] [Full Text] [Related]

  • 28. Low MSAFP and new biochemical markers for Down syndrome: implications for genetic counselors.
    Kloza EM.
    Birth Defects Orig Artic Ser; 1990 May 13; 26(3):31-43. PubMed ID: 1709365
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The importance of genetic counseling before amniocentesis.
    Cohn GM, Gould M, Miller RC, Habecker-Green J, Macri CJ, Gimovsky ML.
    J Perinatol; 1996 May 13; 16(5):352-7; quiz 358-9. PubMed ID: 8915933
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Maternal serum alpha-fetoprotein prenatal screening for Down syndrome.
    Boots LR, Davis RO, Foster JM, Goldenberg RL.
    Ala Med; 1989 Jul 13; 59(1):25-7. PubMed ID: 2475015
    [Abstract] [Full Text] [Related]

  • 33. First-year results of routine alpha-fetoprotein testing on prenatal patients in a family practice.
    Weiss BD.
    J Fam Pract; 1988 Mar 13; 26(3):273-80. PubMed ID: 2450166
    [Abstract] [Full Text] [Related]

  • 34. Elevated maternal serum alpha-fetoprotein with low unconjugated estriol and the risk for lethal perinatal outcome.
    Benn PA, Craffey A, Horne D, Ramsdell L, Rodis JF.
    J Matern Fetal Med; 2000 Mar 13; 9(3):165-9. PubMed ID: 10914624
    [Abstract] [Full Text] [Related]

  • 35. Impact of genetic counseling and prenatal diagnosis for Down syndrome and neural tube defects.
    Swerts A.
    Birth Defects Orig Artic Ser; 1987 Mar 13; 23(2):61-83. PubMed ID: 2954594
    [Abstract] [Full Text] [Related]

  • 36. Prenatal screening for congenital nephrosis in east Finland: results and impact on the birth prevalence of the disease.
    Heinonen S, Ryynänen M, Kirkinen P, Penttilä I, Syrjänen K, Seppälä M, Saarikoski S.
    Prenat Diagn; 1996 Mar 13; 16(3):207-13. PubMed ID: 8710773
    [Abstract] [Full Text] [Related]

  • 37. The inadequacy of the current correction for maternal weight in maternal serum alpha-fetoprotein interpretation.
    Drugan A, Dvorin E, Johnson MP, Uhlmann WR, Evans MI.
    Obstet Gynecol; 1989 Nov 13; 74(5):698-701. PubMed ID: 2478941
    [Abstract] [Full Text] [Related]

  • 38. Down syndrome: prenatal risk assessment and diagnosis.
    Newberger DS.
    Am Fam Physician; 2000 Aug 15; 62(4):825-32, 837-8. PubMed ID: 10969860
    [Abstract] [Full Text] [Related]

  • 39. Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects.
    Jaques AM, Collins VR, Haynes K, Sheffield LJ, Francis I, Forbes R, Halliday JL.
    J Med Screen; 2006 Aug 15; 13(1):8-13. PubMed ID: 16569299
    [Abstract] [Full Text] [Related]

  • 40. Routine ultrasonography compared with maternal serum alpha-fetoprotein for neural tube defect screening.
    Norem CT, Schoen EJ, Walton DL, Krieger RC, O'Keefe J, To TT, Ray GT.
    Obstet Gynecol; 2005 Oct 15; 106(4):747-52. PubMed ID: 16199631
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.